In 2020, it became the only diabetic drug to be approved for reducing or preventing the risk of major cardiovascular events (MACE) in patients with type 2 diabetes
By injecting it into the fatty tissue, Semaglutide is gradually absorbed into the bloodstream, ensuring steady and consistent action over time
Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo
Nevertheless, their therapeutic potentials are still subject of debate, particularly given their known gastrointestinal side effects (e.g., nausea, vomiting, and diarrhea), which may limit their application in IBD patients, especially those with clinically active disease (14)